Welcome to our dedicated page for Inspire Medical SEC filings (Ticker: INSP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for Inspire Medical Systems, Inc. (NYSE: INSP), a medical technology company focused on minimally invasive neurostimulation therapy for moderate to severe obstructive sleep apnea. These documents offer detailed insight into how Inspire reports its financial results, risks, and corporate developments.
Annual reports on Form 10-K and quarterly reports on Form 10-Q contain management’s discussion and analysis of financial condition and results of operations, along with risk factor disclosures. In these filings, Inspire describes its dependence on Inspire therapy for revenues, coverage and reimbursement considerations, competition from other therapies and technologies, reliance on third-party suppliers and contract manufacturers, international operations, information technology and cybersecurity risks, and other factors that may affect future performance.
Current reports on Form 8-K document specific material events. Recent 8-K filings have covered quarterly and annual financial results, preliminary and unaudited revenue ranges, expectations regarding the release of valuation allowances on U.S. deferred tax assets, authorization of share repurchase programs, and leadership changes such as the transition and appointment of the Chief Financial Officer. These filings often incorporate press releases and investor presentation materials by reference.
Investors can also review compensatory arrangements and executive employment agreements described in 8-K items, which outline base salary, bonus targets, equity awards, severance terms, and change-of-control provisions for senior executives. Such disclosures provide transparency into Inspire’s governance and incentive structures.
On Stock Titan, Inspire’s SEC filings are updated as they are made available on EDGAR. AI-powered summaries highlight key points from lengthy documents, helping readers quickly identify themes such as revenue drivers tied to Inspire therapy, guidance ranges, risk factors, and notable corporate actions, without replacing the need to consult the full official filings.
Inspire Medical Systems Inc ownership report: Vanguard Capital Management reported beneficial ownership of 1,469,703 shares of Common Stock, representing 5.10% of the class. The filing shows sole voting power for 202,965 shares and sole dispositive power for 1,469,703 shares. The statement clarifies these holdings reflect securities managed by Vanguard Capital Management LLC and specified affiliates.
Inspire Medical Systems ownership filing: Vanguard Portfolio Management reports beneficial ownership of 1,644,767 shares of Common Stock, representing 5.71% of the class. The filer states sole dispositive power over 1,644,767 shares and sole voting power for 7,594 shares. The disclosure notes holdings include Vanguard funds and managed accounts over which Vanguard exercises dispositive power.
Broader Shelley G reported acquisition or exercise transactions in this Form 4 filing.
Inspire Medical Systems director Shelley G. Broader received 342 shares of Common Stock as a stock grant. The shares were valued at $52.07 per share and were issued in lieu of cash fees under the company’s Non-Employee Director Compensation Policy. Following this routine compensation award, Broader directly holds a total of 4,909 shares of Inspire Medical Systems Common Stock.
Inspire Medical Systems, Inc. director Georgia Melenikiotou received 307 shares of common stock as a grant classified as a “grant, award, or other acquisition.” These shares were issued at $52.07 per share in lieu of cash fees under the company’s Non-Employee Director Compensation Policy, bringing her direct holdings to 4,473 shares.
Ellis Gary Lee reported acquisition or exercise transactions in this Form 4 filing.
Inspire Medical Systems director Ellis Gary Lee received 518 shares of Common Stock as a stock award. The shares were granted at a value of $52.07 per share and were received in lieu of cash fees under the company’s Non-Employee Director Compensation Policy. Following this award, Lee directly holds 7,276 shares of Inspire Medical Systems common stock.
Tansey Casey M reported acquisition or exercise transactions in this Form 4 filing.
Inspire Medical Systems director Casey M. Tansey received a grant of 308 shares of Common Stock on April 15, 2026, as stock compensation in lieu of cash fees under the company’s Non-Employee Director Compensation Policy, at a reference price of $52.07 per share.
Following this award, Tansey directly holds 22,724 shares. Additional shares are reported as held indirectly through two family irrevocable trusts, each holding 500 shares of Common Stock.
The Vanguard Group filed Amendment No. 4 to a Schedule 13G/A reporting its relationship to Inspire Medical Systems common stock. The filing states that, following an internal realignment effective January 12, 2026, certain Vanguard subsidiaries will report separately under SEC Release No. 34-39538. The filing discloses amount beneficially owned: 0 and percent of class: 0%.
Inspire Medical Systems is asking shareholders to vote at a fully virtual annual meeting on April 30, 2026. The proxy seeks approval to re-elect three Class II directors, ratify Ernst & Young as auditor for 2026, and hold advisory votes on executive pay and how often that say‑on‑pay vote should occur.
Shareholders are also asked to approve declassifying the board so all directors stand for annual election starting with the 2029 meeting, amend and restate the 2018 Incentive Award Plan to support broad-based equity compensation, and allow adjournment if more time is needed to pass these items. The proxy highlights 2025 revenue of $912 million, up 14% over 2024, adjusted net income of $72.1 million, adjusted diluted EPS of $2.42, and strong margins as Inspire scales its sleep apnea therapy business.
Inspire Medical Systems, Inc. is asking stockholders to approve governance and compensation proposals at its virtual 2026 Annual Meeting on April 30, 2026. The company reported full-year $912.0 million revenue for 2025, a 14% increase versus 2024, and noted adjusted net income of $72.1 million and adjusted diluted EPS of $2.42. Management highlighted delivery of strong gross margin of 85.4% and adjusted operating margin of 7.3%, the U.S. launch of the Inspire V neurostimulation system, and more than 125,000 patients treated with Inspire therapy.
The proxy includes seven proposals, notably Proposal No. 5 to phase out the classified Board with annual director elections beginning in 2029 and Proposal No. 6 to amend and restate the 2018 Incentive Award Plan to increase authorized shares. The Board recommends FOR all proposals and requests proxies for routine corporate governance, auditor ratification, and an equity plan amendment.